Figure 2
![Response to therapy in patients with a multirefractory ITP. *Cyclophosphamide, n = 1; azathioprine, n = 4; cyclosporine, n = 1; mycophenolate mofetil, n = 2; alemtuzumab, n = 1; high-dose cyclophosphamide followed by autologous HSCT, n = 1. R and CR were defined according to standardized international criteria by platelet count >30 × 109/L with at least a doubling of the baseline value or >100 × 109/L, respectively.2 Nonresponse (NR) was defined as the absence of platelet count increase >30 × 109/L with at least a doubling of the baseline count or the need for rescue therapy (IVIG and/or corticosteroids [CST]).](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/128/12/10.1182_blood-2016-03-704734/4/1625f2.jpeg?Expires=1722076413&Signature=YAdXlUnHBLj0StHO88dIa8SWmQL9sQnk~rcmm0CXvw8~ZAYBQYTg6eXD-UeUzZHNxGdr7NJ-qzS6MbJcoNPcsuBA~6DMCR0R3n6J1DpYXAwwJ3clIXl9D69Qo09vEsYwcPADQoeywc7IKG9zXfIFIB9XmSAXM8vWnIhoiEoo3atdeuGMGqSe1CehUqPMcBUdegQ9kfHGJy4lCMKkSSOsshpHOYWw~UBT0gFboaXad7SmsHdIcr7BJ7xeW82D41cPe~Pg39rk8UfrTRXVtsl7uxIAYIGN4KHxznR7oI1oFWhNARvD~yE4sHURA-jG3IBFRG5RHxcIGu9WQRWeyyVEaw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Response to therapy in patients with a multirefractory ITP. *Cyclophosphamide, n = 1; azathioprine, n = 4; cyclosporine, n = 1; mycophenolate mofetil, n = 2; alemtuzumab, n = 1; high-dose cyclophosphamide followed by autologous HSCT, n = 1. R and CR were defined according to standardized international criteria by platelet count >30 × 109/L with at least a doubling of the baseline value or >100 × 109/L, respectively.2 Nonresponse (NR) was defined as the absence of platelet count increase >30 × 109/L with at least a doubling of the baseline count or the need for rescue therapy (IVIG and/or corticosteroids [CST]).
